TenQ · fact sheet · filings current to · price as of
Procter & Gamble (PG)
Strong business, priced for a lot of it - 23 of 36 checks passed.
Latest close : $146.44, -0.3% on the day; -11.1% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $146.44 |
| Market cap | $340.4B |
| 52-week range | $135.03 - $164.72 |
| P/E | 22.1x |
| P/E, own 11-year median | 22.2x |
| P/S | 3.9x |
| Free cash flow yield | 4.4% |
| Dividend yield | 3.0% |
| Revenue (TTM) | $87.0B |
| Net income (TTM) | $16.0B |
| Free cash flow (TTM) | $15.1B |
| Gross margin | 50.2% |
| Operating margin | 22.7% |
| Return on equity | 29.5% |
| Revenue growth (1y) | +3.3% |
| Revenue CAGR (3y) | +2.0% |
| Debt / equity | 0.63x |
| Cash & short-term investments | $9.9B |
| Shares outstanding | 2,324.4m (cover page of the latest filing, 2026-07-31) |
The score: 23 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is PG stock cheap or expensive right now?
Value · 2 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Procter & Gamble still growing?
Growth · 3 of 6 checks passed. Growing, but with caveats - revenue +3.3% over the last year. chapter →
Does Procter & Gamble make real money?
Quality · 5 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can Procter & Gamble survive a bad year?
Health · 5 of 6 checks passed. A fortress balance sheet - PG can survive a very bad year. chapter →
What does Procter & Gamble hand back to shareholders?
Shareholder returns · 5 of 6 checks passed. Owners are paid reliably and affordably, and the share count is not eroding their stake. chapter →
Which way is PG trending?
Trend analysis · 3 of 6 checks passed. Mixed signals from the market - some trends up, some rolling over. chapter →
Are insiders buying or selling PG?
Open-market buys: $0.00 · sells: $7M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Amgen (AMGN) · Abbott Laboratories (ABT) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.